This is a very interesting contribution. We know the response rate to first line EGFR TKIs is 70-80%, but not 100%, and we also see wide variability in how long patients go without progression on initial EGFR TKI therapy. Though we have long oversimplified by presuming that patients with an activating EGFR mutation won't have any other relevant mutations, we are beginning to see that additional mutations may contribute to the variability in outcomes we're seeing.

It will be great to see further work from other sources corroborate these observations, but this is very provocative.